Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) Research & Development (2020 - 2025)

Rapid Micro Biosystems' Research & Development history spans 6 years, with the latest figure at $3.2 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 5.35% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.6 million, a 6.81% decrease, with the full-year FY2025 number at $13.6 million, down 6.81% from a year prior.
  • Research & Development hit $3.2 million in Q4 2025 for Rapid Micro Biosystems, down from $3.5 million in the prior quarter.
  • Over the last five years, Research & Development for RPID hit a ceiling of $3.8 million in Q1 2024 and a floor of $2.1 million in Q1 2021.
  • Historically, Research & Development has averaged $3.2 million across 5 years, with a median of $3.2 million in 2023.
  • Biggest five-year swings in Research & Development: surged 87.86% in 2021 and later decreased 13.73% in 2025.
  • Tracing RPID's Research & Development over 5 years: stood at $2.9 million in 2021, then increased by 19.19% to $3.4 million in 2022, then decreased by 2.5% to $3.3 million in 2023, then rose by 2.53% to $3.4 million in 2024, then fell by 5.35% to $3.2 million in 2025.
  • Business Quant data shows Research & Development for RPID at $3.2 million in Q4 2025, $3.5 million in Q3 2025, and $3.2 million in Q2 2025.